{
    "title": "New GSK maintains strong start, but Zantac litigation looms large",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11380669/GSK-lifts-2022-forecast-stronger-expected-quarter.html",
    "date": "2022-11-02",
    "keywords": [
        "business",
        "gsk",
        "quarter",
        "year",
        "vaccine",
        "forecast",
        "analyst",
        "zantac",
        "profit",
        "time",
        "charge",
        "grover",
        "medicine",
        "consumer",
        "covid19",
        "shingrix",
        "covid",
        "drug",
        "wednesday",
        "field",
        "handful",
        "consensus",
        "drugmaker",
        "virus",
        "company",
        "pound",
        "comment",
        "start",
        "standalone",
        "prescription",
        "health",
        "division",
        "underperformance",
        "relative",
        "market",
        "set",
        "string",
        "blockbuster",
        "revenue",
        "therapy",
        "xevudy",
        "revolt",
        "trial",
        "success",
        "litigation",
        "month",
        "pence",
        "trade",
        "afternoon",
        "point",
        "session",
        "stock",
        "overhang",
        "raft",
        "carcinogen",
        "forerunner",
        "pfizer",
        "boehringer",
        "ingelheim",
        "sanofi",
        "worstcase",
        "scenario",
        "merck",
        "amp",
        "cos",
        "painkiller",
        "vioxx",
        "currency",
        "exchange",
        "favour",
        "arsenal",
        "basis",
        "omicron",
        "operating",
        "hike",
        "meanwhile",
        "priority",
        "review",
        "rsv",
        "decision",
        "respiratory",
        "structure",
        "safety",
        "editing",
        "mark",
        "potter",
        "jason",
        "jane",
        "merriman"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}